checkAd

     176  0 Kommentare Arvinas, Inc. Announces Pricing of $400 Million Public Offering of Common Stock - Seite 2

    Forward-Looking Statements

    This press release contains forward-looking statements that involve substantial risks and uncertainties, including statements regarding the proposed public offering, including the closing of the public offering. All statements, other than statements of historical facts, contained in this press release, including statements regarding our strategy, future operations, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

    We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make as a result of various risks and uncertainties, including but not limited to satisfaction of customary closing conditions related to the public offering, whether we will be able to conduct, complete and receive results from clinical trials for our product candidates on our expected timelines, or at all, whether our cash resources will be sufficient to fund our foreseeable and unforeseeable operating expenses and capital expenditure requirements on our expected timeline and other important factors discussed in the “Risk Factors” sections contained in our quarterly and annual reports on file with the SEC. The forward-looking statements contained in this press release reflect our current views with respect to future events, and we assume no obligation to update any forward-looking statements except as required by applicable law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this release.

    Investors:
    Will O’Connor, Stern Investor Relations
    ir@arvinas.com

    Media:
    Kirsten Owens, Arvinas Communications
    kirsten.owens@arvinas.com


    Seite 2 von 2




    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Arvinas, Inc. Announces Pricing of $400 Million Public Offering of Common Stock - Seite 2 NEW HAVEN, Conn., Dec. 15, 2020 (GLOBE NEWSWIRE) - Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its PROTAC Discovery Engine, today announced the …

    Schreibe Deinen Kommentar

    Disclaimer